Teladoc AI Stock Analysis
Want to see TDOC full AI Analyst Report?
Teladoc (TDOC) AI Stock Analysis
Teladoc
(NYSE:TDOC)
The score is driven primarily by improving operating efficiency and consistently positive free cash flow, supported by a constructive earnings update (EBITDA beat and raised guidance). These positives are tempered by ongoing net losses and weak revenue trajectory, while technicals show strong momentum but very overbought conditions. Valuation remains a headwind due to negative earnings and no dividend yield provided.
Teladoc Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down sales by region (U.S. versus international), showing where revenue is concentrated and where growth opportunities or regulatory and currency risks exist. A heavy U.S. mix can imply steadier reimbursement while international growth offers upside—or added complexity.
U.S. revenue has softened after its peak while international has been the fastest-growing geography — meaning Teladoc’s near-term growth now depends more on overseas and non-cash businesses. Management’s call confirms this: Integrated Care is driving international, with high single‑digit organic growth and expanding margins, but BetterHelp’s pivot to insurance and a pullback in international ad spend creates execution risk for global topline. In short, durable margin recovery hinges on Integrated Care scaling abroad while BetterHelp’s transition determines whether international growth stays broad‑based or concentrated.
Teladoc (TDOC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.47B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.19M
- Price to Earnings (P/E)
- -9.4
- Beta (1Y)
- 1.62
- Revenue Growth
- -2.38%
- EPS Growth
- 32.73%
- Country
- US
- Employees
- 5,124
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Teladoc Business Overview & Revenue Model
Company Description
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and lo...
How the Company Makes Money
Teladoc primarily generates revenue by selling access to its virtual care platform and clinical services to business and institutional customers (such as employers and health plans) as well as through certain direct-to-consumer arrangements. A major...
Teladoc Earnings Call Summary
The call was positive overall. Management reported a solid third quarter with adjusted EBITDA above guidance, expanding margins, strong cash flow and liquidity, improved leverage, Integrated Care growth, and accelerating BetterHelp insurance traction. These positives outweighed the ongoing BetterHelp cash pay decline, lower total revenue and paying users, margin pressure, and continued uncertainty around the business transition.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Teladoc expects consolidated revenue of $2.39 billion to $2.44 billion, adjusted EBITDA of $277 million to $303 million, free cash flow of $135 million to $165 million, stock based compensation expense below $50 million, and a full year net loss per share of a loss of $0.95 per share to a loss of $0.75 per share; fourth-quarter consolidated revenue is expected to be $569 million to $615 million and adjusted EBITDA $74 million to $100 million. Integrated care revenue growth is expected to be 1.1% to 2.1%, adjusted EBITDA margin 16% to 16.6%, fourth-quarter revenue flat to up 3.8%, and fourth-quarter adjusted EBITDA margin 14.5% to 16.8%; BetterHelp revenue is expected to decline 16.1% to 12.9%, insurance revenue is expected to be $99 million to $105 million, adjusted EBITDA margin 2.7% to 4.3%, fourth-quarter revenue down 31.5% to down 18.5%, insurance revenue $32 million to $38 million, and adjusted EBITDA margin 9.2% to 15.1%. For 2027, Teladoc expects continued growth in insurance, a goal of sequential quarterly improvement over the course of 2027, and a goal of achieving an annualized revenue run rate of at least $200 million as we exit 2027; BetterHelp advertising and marketing spending is expected to decline in the mid to high-20% range for the full year in 2027.
Teladoc Financial Statement Overview
Summary
Cash flow is a clear strength (positive operating cash flow and free cash flow in all periods, including TTM), and margins are improving (higher gross margin and meaningfully better EBITDA margin). Offsetting this, TDOC remains unprofitable (negative net margin and ROE) and revenue momentum is weak/declining in the most recent period.
Income Statement
36NegativeBalance Sheet
54NeutralCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.47B | 2.53B | 2.57B | 2.60B | 2.41B | 2.03B |
| Gross Profit | 1.81B | 1.76B | 1.82B | 1.84B | 1.66B | 1.38B |
| EBITDA | 236.09M | 147.30M | 174.06M | 138.22M | 50.32M | -19.37M |
| Net Income | -154.82M | -200.32M | -1.00B | -220.37M | -13.66B | -428.79M |
Balance Sheet | ||||||
| Total Assets | 2.78B | 2.86B | 3.52B | 4.39B | 4.70B | 17.73B |
| Cash, Cash Equivalents and Short-Term Investments | 849.91M | 781.08M | 1.30B | 1.12B | 918.18M | 896.02M |
| Total Debt | 1.04B | 1.04B | 1.58B | 1.59B | 1.59B | 1.28B |
| Total Liabilities | 1.48B | 1.47B | 2.03B | 2.07B | 2.39B | 1.69B |
| Stockholders Equity | 1.29B | 1.39B | 1.49B | 2.33B | 2.31B | 16.05B |
Cash Flow | ||||||
| Free Cash Flow | 232.65M | 285.46M | 282.89M | 193.67M | 172.81M | 185.46M |
| Operating Cash Flow | 268.38M | 294.36M | 293.68M | 350.02M | 189.29M | 193.99M |
| Investing Cash Flow | -143.25M | -266.00M | -124.05M | -156.35M | -167.74M | -72.98M |
| Financing Cash Flow | -53.00K | -551.65M | 8.31M | 10.85M | 6.50M | 40.95M |
Teladoc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Positive. The current price of 8.06 is below the 20-day moving average (MA) of 8.14, above the 50-day MA of 6.85, and above the 200-day MA of 6.64, indicating a bullish trend. The MACD of 0.63 indicates Positive momentum. The RSI at 59.17 is Neutral, neither overbought nor oversold. The STOCH value of 20.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TDOC.
Teladoc Risk Analysis
Teladoc disclosed 58 risk factors in its most recent earnings report. Teladoc reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksTeladoc Peers Comparison
Overall Rating
HNGE81Outperform
DOCS80Outperform
OMDA69Neutral
TDOC56Neutral
AMWL51Neutral
VSEE40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $9.30B | 55.06 | 50.47% | ― | 49.86% | ― | |
| 80Outperform | $5.54B | 40.89 | 14.81% | ― | 6.48% | -43.66% | |
| 69Neutral | $817.04M | 55.36 | 5.67% | ― | 43.34% | ― | |
| 56Neutral | $1.47B | -9.37 | -11.63% | ― | -2.38% | 32.73% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $189.94M | -3.21 | -25.49% | ― | -20.30% | 52.30% | |
| 40Underperform | $175.37K | -0.01 | -400.87% | ― | -30.28% | 38.11% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TDOC | Teladoc Inc. | 8.06 | 1.30 | 19.23% | |
| AMWL | American Well Corporation | 11.03 | 7.25 | 191.80% | |
| DOCS | Doximity, Inc. | 30.67 | -15.75 | -33.93% | |
| VSEE | Vsee Health, Inc. | 0.20 | -51.80 | -99.62% | |
| HNGE | Hinge Health, Inc. Class A | 114.53 | 69.17 | 152.49% | |
| OMDA | Omada Health, Inc. | 13.17 | -5.00 | -27.52% |
Teladoc Corporate Events
Teladoc Announces Chief Legal Officer Leadership Transition
NeutralOn September 24, 2026, Teladoc Health, Inc. announced that Chief Legal Officer and Secretary Adam C. Vandervoort had resigned with good reason under his executive severance agreement, effective November 1, 2026. He will continue to provide unpaid adv...
Teladoc Health Appoints Michael Grasher as New CFO
PositiveOn August 31, 2026, Teladoc Health appointed veteran financial executive Michael Grasher as Chief Financial Officer, while Charles Divita III remained Chief Executive Officer. Grasher brings more than three decades of experience in insurance and fina...
Teladoc Announces Upcoming Retirement of Longtime Board Director
NeutralTeladoc Health, Inc., a leading telehealth provider serving consumers, employers and health plans, offers virtual medical and digital health services aimed at expanding access to care through remote technology. The company operates in the growing dig...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026
